XML 46 R37.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Acquisition Intangible Assets (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Feb. 24, 2021
Dec. 31, 2020
Sep. 30, 2019
Equity method investment carrying value   $ 13,417  
Oncocyte common stock issued (982,318 shares issued at market value) as Additional Purchase Payment 251,238   157,160  
Finite-Lived Intangible Assets, Gross $ 95,174   $ 15,090  
Razor Genomics, Inc. [Member]        
Equity method investment carrying value   $ 13,147   $ 11,245
Cash paid as Additional Purchase Payment for the Razor asset   10,000    
Oncocyte common stock issued (982,318 shares issued at market value) as Additional Purchase Payment   5,756    
Less: cash balance received from Razor for Clinical Trial expenses   (3,352)    
Deferred tax liability generated from the Razor asset   7,564    
Other   169    
Finite-Lived Intangible Assets, Gross [1]   $ 33,284    
[1] This balance will be amortized over the remaining useful life of the Razor asset, approximating 8.5 years, as of the February 24, 2021 acquisition date, with the amortization expense included in “Cost of revenues – amortization of acquired intangibles” on the condensed consolidated statements of operations.